MedTrace Logo

Safety & Efficacy of Low Dose Aspirin / Ivermectin Combination Therapy for Treatment of Covid-19 Patients

NCT04768179 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 490

Last updated 2021-02-24

No results posted yet for this study

Summary

COVID-19, caused by the novel Severe Acute Respiratory Syndrome Corona Virus 2 (SARSCoV-2), has become a global pandemic. Fortunately, most of the COVID-19 cases confirmed are categorized as mild for whom home- based symptomatic management with monitoring of clinical deterioration is recommended. Despite providing symptomatic management, a therapeutic drug that would limit the course of infection is greatly needed to stop COVID-19 disease progression. Considering the current SARS-CoV-2 epidemiology and the legitimate rash towards appropriate therapies, our study seeks to evaluate the safety and efficacy of low dose aspirin and ivermectin combination therapy in COVID-19 patients.

Conditions

  • Covid19

Interventions

DRUG

3-dayIVM 200 mcg/kg/day/14-day 75mgASA/day + standard of care (intervention 1)

Low dose aspirin for 14 days plus ivermectin at 200 mcg/kg/day or 600 mcg/kg/day for 3 days

Sponsors & Collaborators

  • Ministry of Health, Uganda

    collaborator OTHER_GOV

  • Mbarara University of Science and Technology

    collaborator OTHER

  • Joint Clinical Research Center

    collaborator OTHER

  • Makerere University

    lead OTHER

Principal Investigators

  • Jackson Mukonzo, PhD · Makerere University, college of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-19
Primary Completion
2021-06-30
Completion
2021-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04768179 on ClinicalTrials.gov